arrow
A

Adam Gater

GlaxoSmithKline
H指数:16
被引数:1,107

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer

将患者意见纳入属性和水平选择以进行偏好研究:一项在非肌肉浸润性膀胱癌中的定性研究

2026-03-110
OAAI
Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials

退出访谈:考察血管运动症状相关的情绪变化及工作/生产力影响——接受Elinzanetant治疗的绝经后女性在III期临床试验中的观点

2025-07-120
OA
Patient Experience of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Qualitative Exploration of Signs, Symptoms, and Health-Related Quality of Life Impacts

慢性炎症性脱髓鞘性多发性神经病(CIDP)患者体验:对体征、症状及健康相关生活质量影响的定性探究

2025-04-300
OA
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
2022-08-257
OAAI
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD (vol 11, pg 221, 2021)
2021-06-280
OAAI
Patients' and clinicians' perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

患者和临床医生对子宫内膜异位症症状日记 (ESD) 和子宫内膜异位症影响量表 (EIS) 的项目重要性,评分和临床意义差异的看法

2021-01-063
OAAI